Previous 10 | Next 10 |
The U.S. FDA has granted Fast Track designation to Inhibrx's (INBX) INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma, a form of bone cancer.Fast Track designation is granted by the FDA to facilitate the development and expedite the review of ...
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year PR Newswire SAN DIEGO , Ja...
Inhibrx ([[INBX]] -8.2%) has announced results from Part 1 of the Phase 1 dose escalation trial evaluating INBRX-106, a hexavalent OX40 agonist, for the treatment of solid tumors.The 4-part trial is designed to determine the safety profile and identify the maximum tolerated dose and/or recomm...
Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...
Gainers: Sutro Biopharma (STRO) +33%, Merrimack Pharmaceuticals (MACK) +18%, Evogene (EVGN) +18%, BioCryst Pharmaceuticals (BCRX) +16%, PDS Biotechnology (PDSB) +15%.Losers: Precision BioSciences DTIL -21%, Cortexyme CRTX -17%, Chembio Di...
Inhibrx (INBX): Q3 GAAP EPS of -$0.77 misses by $0.07.Cash and equivalents totaled $127.7M.Press Release For further details see: Inhibrx EPS misses by $0.07
Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford - Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th - Additional $20...
Inhibrx (INBX) has announced updated interim results from Phase 1 trial evaluating efficacy and safety of INBRX-109 in solid tumors including sarcomas. Results include from chondrosarcoma cohort, a rare type of cancer that usually begins in the bones, but can sometimes occur in the soft ...
Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients - Disease control observed in 92% of patients - Conference call to be held today at 2:30pm PT PR Newswire SAN DIEGO, Nov. 11, 2020 SAN DIEGO , Nov....
Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences PR Newswire SAN DIEGO, Nov. 5, 2020 SAN DIEGO , Nov. 5, 2020 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pip...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-07-23 06:30:08 ET JMP Securities analyst issues MARKET PERFORM recommendation for INBX on July 23, 2024 04:40AM ET. The previous analyst recommendation was Outperform. INBX was trading at $13.49 at issue of the analyst recommendation. The overall analyst consensus :...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...